Ibrutinib effective in elderly patients with CLL

Researchers from the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), along with those from MD Anderson Cancer Center will be presenting interim findings at the June meeting of the American Society of Clinical Oncology of a Phase I/II clinical trial evaluating the experimental drug ibrutinib (PCI-32765).

The trial evaluated the oral drug ibrutinib (PCI-32765) in the treatment of elderly patients with chronic lymphocytic leukemia (CLL).

The interim findings suggest that ibrutinib has a low toxicity profile with few side effects but a high response rate in the older patient population. Typically these patients receive fludarabine, which causes many side effects and can quickly become useless as resistance builds.

CLL is the most frequently diagnosed form of leukemia, accounting for over 16,000 new cases in the US annually, and between 4000 and 5000 people die from CLL each year.

Source: Medical News Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap